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An epidemiologic and seroprevalence survey was con-
ducted (n=830) to assess the proportion of persons
exposed to hantavirus in IX Region Chile, which accounts
for 25% of reported cases of hantavirus cardiopulmonary
syndrome. This region has three geographic areas with dif-
ferent disease incidences and a high proportion of aborigi-
nals. Serum samples were tested for immunoglobulin (Ig) G
antibodies by enzyme-linked immunosorbent assay against
Sin Nombre virus N antigen by strip immunoblot assay
against Sin Nombre, Puumala, Río Mamoré, and Seoul N
antigens. Samples from six patients were positive for IgG
antibodies reactive with Andes virus; all patients lived in the
Andes Mountains. Foresting was also associated with
seropositivity; but not sex, age, race, rodent exposure, or
farming activities. Exposure to hantavirus varies in different
communities of IX Region. Absence of history of pneumo-
nia or hospital admission in persons with specific IgG anti-
bodies suggests that infection is clinically inapparent.
H
antaviruses, RNA-containing viruses, compose a
genus within the family Bunyaviridae. The natural
reservoirs of the pathogenic New World hantaviruses are
rodents of the family Muridae, subfamily Sigmodontinae,
in which a chronic and asymptomatic infection develops
(1). Hantavirus is a zoonosis transmitted from rodents to
humans by inhaling contaminated aerosols from feces,
urine, and saliva of infected mice (2).
Human infection with hantaviruses have been associat-
ed with two diseases. One is the hemorrhagic fever with a
renal syndrome (HFRS) caused by Hantaan, Puumala,
Seoul, and Dobrava/Belgrade viruses, first recognized dur-
ing the Korean War in 1950 to 1953. HFRS occurs mainly
in Asia and Europe; death rates range from 0.1% to 15%
(3,4). The other disease, a severe respiratory illness known
as hantavirus cardiopulmonary syndrome (HCPS), occurs
in the Americas and has a death rate of 40% (1,5–7). We
prefer the term hantavirus cardiopulmonary syndrome to
an alternative term, hantavirus pulmonary syndrome,
because most deaths associated with HCPS are related to
cardiac failure rather than pulmonary failure, and this
aspect of the syndrome remains underappreciated by prac-
titioners and others.
HCPS has been identified in several countries in North
and South America and is caused by different hantavirus-
es: Sin Nombre in North America, Juquitiba virus in Brazil
(8), Laguna Negra virus in Paraguay and Bolivia (9,10),
Andes in Argentina and Chile (11,12), Choclo virus in
Panama (13), and several subspecies or viral genotypes of
Andes virus in Argentina (e.g., Oran, Lechiguanas, et al.)
(14–16).
In 1995, Andes virus was first identified in the
Argentinean Patagonia and was recognized in central and
southern regions of Chile. The reservoir is the long-tailed
pygmy rice rat (Oligoryzomys longicaudatus), a species
that occurs primarily in temperate forest (17). 
Since HCPS emerged in Chile, 287 cases have been
confirmed as of March 2003, causing a substantial impact
on the public health system; the death rate for HCPS in
Chile has exceeded 40%. In addition to the 287 cases of
HCPS, 17 cases of mild infection with no cardiopulmonary
involvement have been reported, demonstrating that han-
tavirus infection may have variability in its expression.
Serologic studies have established both clinically asymp-
tomatic infections and symptomatic infections not recog-
nized at the time as hantavirus infection (18–23).
The phenomenon of clinically nonapparent infections
varies in different areas and populations of the Americas.
In the United States, the proportion of infection versus dis-
ease is thought to be close to 1% (i.e., disease develops in
most of the infected patients, and human population sero-
prevalence varies between 0.2% to 1.7%) (4,24,25).
Seroprevalence studies in South America, however, have
shown that some populations have had much more fre-
quent exposure to hantaviruses in the absence of known
clinical manifestations, as seen in some populations native
to Paraguay and Northern Argentina (40% and 17%,
respectively) (26), the general population in Aysen,
Southern Chile (2.0% and 13.1% in urban and rural areas,
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and 13.1%, respectively) (28,29), and recently in Panama
(30%) (13). The populations with the highest seropreva-
lence were indigenous persons rather than those of
European ancestry.
Two hypotheses have been proposed to explain these
phenomena. The first one presumes that strains in South
America are of lesser pathogenicity, though in many cases
nonpathogenic viruses have yet to be detected in local
rodent populations. The second hypothesis involves the
existence of at least two variables: the nature of the expo-
sure and genetic constitution of the host population. The
high seroprevalence seen in Paraguay (26) could be caused
by a higher resistance in the aboriginal population and
greater exposure to the virus in some regions. The preva-
lence and high case-fatality ratios seen in North America
might be the result of a lower exposure, a lesser genetic
resistance to disease, or both.
More than 20 strains of hantaviruses are known world-
wide; not all of them are associated with human disease.
The observations discussed in this article suggest the need
to study whether hantaviruses of lesser pathogenicity and
other clinical entities until now unrecognized may occur in
areas where the seroprevalence is high and disease inci-
dence is low (11,14–16,18). For example, hantaviruses
previously thought to be endemic only in Europe and Asia
have also been recognized in the North American continent
(30–32).
To study the seroprevalence of hantavirus in Chile, we
studied the general population in the IX Region for the rea-
sons that follow. This area is ranked third among those
affected by HCPS, accounting for 25% of the known cases
in Chile. Three different areas can be distinguished on the
basis of geographic features in relation to the two moun-
tain ranges that traverse the region (the Pacific Coast and
the coastal range [Coastal], the Central Valley [Central],
and the pre-Andean Region [Andean]). The Mapuche, the
main native ethnic population of Chile, account for 26.3%
of the total regional population. Members of the tribe can
readily be identified from surnames, which are derived
from both parents. Therefore, we were able to study the
seroprevalence of hantavirus in the same region but in
areas having different incidence rates of the disease and
evaluate the asymptomatic infection in the Mapuche abo-
riginal population. 
Methods
Study Design and Area
We conducted a cross-sectional epidemiologic and
serologic survey to determine the prevalence of IgG anti-
bodies against hantavirus N antigen in the adults living in
nine communities of the IX Region of Chile. The IX
Region of Chile is located in the southern part of the coun-
try, between parallel 37° and 40° South and the meridians
70° and 74° East (Figure). The region has a surface area of
31,842.3 km2 and 781,242 inhabitants in 31 communities;
of the total population, 38.71% is rural. The characteristics
of these populations can be distinguished according to geo-
graphic features. The Mountainside Andes range (Andean)
is rural area with small towns; the population there is pri-
marily sustained with farming, woodcutting, and tourist
services. The population composes 13.8% of the region’s
total population, yet accounts for 82% of HCPS cases. The
Central Valley intermediate depression (Central) is a pre-
dominantly urban area in which the main sources of
income are industry, farming, and ranching. Temuco, the
capital and main urban center, is located in this area.  The
Central Valley contains 67.3% of the total population and
accounts for 5.9% of HCPS cases. Coastal inhabitants
account for 19% of the region’s population; the communi-
ty sustains itself with farming and forestry activities, fish-
ing, and tourism. Twelve percent of HCPS cases originate
in this area.
Sample Design
The sample included 847 persons, enough to give us
accurate point seroprevalence given estimated seropreva-
lence rates of 7%, 3%, and 5% for the Andean, Central,
and Coastal areas, respectively, as derived from previous
studies in the country (27) and the distribution of HCPS
cases in the region. The sample was designed to be repre-
sentative of each community according to information
available from the National Statistics Agency about popu-
lation sex, ethnicity, age distribution, and rural-urban pro-
portion. Persons were contacted in their homes with a pre-
determined plan that included the selection of the housing
blocks to be studied, the home at which to start enrollment,
and how to proceed thereafter. Only one person was
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Figure. Geographic IX Region, Chile, and hantavirus seropreva-
lence in the tested communities of the IX Region. HCPS,
Hantavirus cardiopulmonary syndrome.
HCPSenrolled in each household contacted. That person was
informed of the study, signed an informed consent, and
agreed to answer a questionnaire and donate a sample of
blood. Only persons >15 years of age who were free of any
current febrile respiratory illness were asked to enroll. The
epidemiologic questionnaire, previously validated in the
community, requested information about sex, age, race,
residency, labor activity, rodent exposure at home or work,
cardiorespiratory disease history, hospital admissions, and
direct contact with HCPS patients.
Nine communities were included, three per geographic
area. Curacautín, Melipeuco, and Pucón (Figure) were
chosen as representative of the Andean area (n=277);
Victoria, Temuco, and Loncoche from the Central area
(n=279); and Purén, Carahue, and Toltén from the Coastal
area (n=291). The Andean and Coastal areas were consid-
ered rural; the Central area was considered to be a compos-
ite of rural and urban. Persons were classified as Mapuches
when they had at least one surname of Mapuche deriva-
tion. The study was approved by the Catholic University
Ethics Committee.
Collection, Processing, and Analysis of Samples
Blood samples were collected, transported, and cen-
trifuged the same day. Serum samples were kept frozen at
–20°C and sent for analysis to the Laboratory of Virology
at the Pontificia Universidad Católica de Chile, Santiago,
Chile. An enzyme-linked immunosorbent assay (ELISA)
was performed to detect hantavirus-specific immunoglob-
ulin (Ig) G antibodies in all samples. 
ELISA was performed as described (33,34) by using
recombinant antigen for the Sin Nombre strain (produced
in Escherichia coli and provided by Centers for Disease
Control and Prevention [CDC]), which crossreacts with all
American hantaviruses. Briefly, serial dilutions (1:100,
1:400, 1:1,600, and 1:6,400) of patient serum samples
were incubated for 1 h at 37°C in antigen-coated, 96-well
plates. Peroxidase-coupled anti-human IgG was used as
secondary antibody and incubated 1 h at 37°C. After sub-
strate reaction, plates were read at 414 nm. 
The net absorbance values are results of the hemiplates
absorbance subtraction with and without antigen. To be
considered positive, the net absorbance values for a sam-
ple had to be >0.2 in the 1:100 and 1:400 dilutions, and the
sum of all net absorbance values had to be >0.95. Positive
serum samples were tested twice and verified to be posi-
tive at CDC. 
A confirmatory strip immunoblot assay (SIA) was per-
formed an all positive samples (B.H.). Four recombinant N
antigens from Sin Nombre, Puumala, Rio Mamoré, and
Seoul hantaviruses were fixed onto a nitrocellulose mem-
brane by vacuum. Serum samples (1:200) were incubated
with the strips and alkaline phosphatase-coupled anti-
human IgG added. Reactivity was estimated visually, and
each band given an intensity value on a four-point scale, as
previously described (35,36). We regarded a sample as
positive for antibodies when reactive to both Sin Nombre
and Rio Mamoré on the basis of the presumption that anti-
bodies to Andes virus will always react to closely related
Rio Mamoré and generally will crossreact with the other
sigmodontine rodent-borne virus, Sin Nombre. A sample
was regarded as confirmed seropositive when the serum
was reactive in the ELISA and confirmed by the SIA.
Fisher exact test was used for the analysis of independent
variables. A p value <0.05 was considered significant.
Results
Sample Population Characteristics
A total of 829 persons were included in the study, with
271, 272, and 286 from the Andean, Central, and Coastal,
respectively. The age range was 15–88 years of age (mean
39.4 years of age); 47.6% were men, and 18.3% were of
Mapuche origin. In all, 73.3% of the sampled population
was considered rural. Men worked in farming, forestry, or
both in 61.8% of the cases; 62.2% of the women were
housewives. A history of exposure to rodents, their excre-
ta, or both at home was reported in 88.0% of enrolled per-
sons; 54.6% reported exposure at work.
Serology
Six (0.72%) samples were hantavirus antibody-positive
by both ELISA and SIA. The samples came from persons
who lived in the Andean area, giving a seroprevalence of
2.15% (6/271) for this area, significantly higher than the
other two regions studied (p=0.0001). The seropositive
cases belonged to each of the three counties studied; how-
ever, relative frequencies varied: Curacautín, 2.6%
(2/132); Melipeuco, 6.1% (2/33); and Pucón, 2.0%
(2/100). All three counties have previously had HCPS
cases reported (Figure). As shown in Table 1, four case-
patients were male, and two were Mapuche. The case-
patients ranged from 28 to 76 years of age, with a mean of
52.8 years of age. Seropositivity could not be associated
with sex (p=0.43), race (p=0.30), or age (p=0.18). Five of
the case-patients worked in farming or forestry, although
only forestry had a significant association with seroposi-
tivity (p=0.018), meaning the risk for infection was 10
times higher (relative risk 9.72; confidence interval 1.15 to
82.44). Five of the case-patients said they had been
exposed to rodents or their excreta either at home or work.
This exposure, however, did not reach statistical signifi-
cance (p=0.1 and p=1.0, respectively). The sixth case-
patient was not exposed to rodents; however, he had been
working in a large shed, the woods, and a sawmill; he also
had been weeding. Finally, none of the six antibody-posi-
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tory of pneumonia, or hospital admission.
Discussion
This study shows serologic evidence of past infection
by hantavirus in the Chilean population. The hantavirus
associated with symptomatic infections in Chile is Andes
virus, identified in patient blood samples by reverse tran-
scription-polymerase chain reaction (RT-PCR) and recent-
ly isolated from human blood (12,37).
Our results show the global seroprevalence to han-
tavirus in the adult general population in the IX Region to
be 0.72% (ranging from 0 to 6%, depending on the com-
munity). Seroprevalence is significantly higher in the
Andes rural area, consistent with the observed elevated
incidence of HCPS disease in this area of Region IX
between 1997 and 2000 (Table 2). This geographic distri-
bution is probably related to the great tracts of native for-
est, where Chusquea quila, a bamboo-like shrub that pro-
tects and feeds the carrier rodent, is abundant. Moreover,
the increasing development of the forestry industry plus an
increase in the rodent population caused by the favorable
climatic condition because of the El Niño effect have
caused humans and mice to interact closely.
We did not find an association between seroprevalence
and reported exposure to rodents, probably because this
type of exposure is frequent in all groups in the region,
occurring both at work and at home. The exposure to
rodents or their excreta is necessary but apparently not suf-
ficient to acquire the infection. Presumably an exposure to
a specific reservoir mouse or virus carrier, human behav-
ior, and biologic factors are important.
Forestry is associated with a higher risk for infection.
This labor, whether in the woods or at sawmills, is per-
formed almost exclusively by men; both men and women
share farm work in most instances. This finding may
explain why a higher proportion of HCPS develops in men
(75% of reported cases). However, any apparent associa-
tion between hantavirus exposure and a particular occupa-
tion does not necessarily implicate these occupations as a
risk factor. In fact, occupation may be a marker for living,
sleeping, or housing conditions that constitute the proxi-
mate risk factor for exposure. Indoor exposure to rodents
is common in patients with HCPS (38).
On the basis of these results, we argue that infections by
hantavirus follow a gradient of exposure to the virus in the
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Table 1. Relationship between independent variables and 
seropositivity to hantaviruses, IX Region, Chile 
Variables 
Seropositive 
(total)  p value  RR (95% CI)
a 
Sex       
Male  4 (395)  0.43   
Female  2 (435)     
Age       
15–44 y of age  2 (550)  0.18   
>44 y of age  4 (280)     
Race       
Mapuche  2 (151)  0.30   
Other  4 (679)     
Area       
Andean  6 (271)  0.0001
a  NA
b 
Central  0 (273)     
Coastal  0 (286)     
Risk activity or labor       
Agrarian
c       
 No  activity  1 (271)     
  Two or more  4 (341)  0.38   
Foresting
d       
 No  activity  1 (279)     
 With  activity  5 (135)  0.018  9.72  
(1.15 to 82.44) 
Exposure to rodents       
Peridomestic  5 (731)  0.10   
Laboral  5 (453)  1.00   
ap <0.05; p values were determined by using 2-tailed Fisher exact test; RR, 
relative risk; CI, confidence interval. 
bNot applicable. 
cClearing, shrubbery cutting, working in pastures or cellars. 
dForesting, working at a sawmill. 
Table 2. Incidence of hantavirus cardiopulmonary syndrome (HCPS) and seroprevalence in Chile’s IX Region according to geographic area 
Region 
  Global  Andean (A)  Central (B)
b  Coastal  p value
a  (A vs. B)  RR (95% CI)
a 
Disease         
Cases  34  29  1  4 
Population  781,242  127,974  424,278  229,190 
0.0001  29.6 (11.46 to 76.47) 
Cumulative Incidence 
(1997-2001) (x10
6)
c  4.35  22.66  0.23  1.74     
Infection         
Seropositive  6  6  0  0 
Sample  829  271  272  286 
Prevalence (%)  0.72  2.15  0  0 
 
0.00013 
 
NA
d 
ap values were determined using 2-tailed Fisher exact test; RR, relative risk; CI, confidence interval. 
bB is Central and Coastal regions combined. 
cChile’s Department of Health, March 2001. 
dNot applicable. IX Region. Our population has a different epidemiologic
profile to those of the aborigines of Paraguay (40%) and
North Argentina (17%) in South America, which have low
seroprevalence, similar to that described for North
American populations, as reported by Vincent (13) and
Ferrer (26). This lower seroprevalence could be because of
a greater pathogenicity and clinical severity in infections
by the prototypical (southern) form of Andes virus, similar
to Sin Nombre virus.
Less pathogenic hantaviruses may cause a greater
amount of asymptomatic infections, as seen for HFRS in
Europe and Asia (seroprevalence 7.9% to 10%, death rate,
0.1% to 15%) (39) and some American hantaviruses
(Laguna Negra in Bolivia and Paraguay, Choclo in
Panama, Oran and Lechiguanas in Argentina) for which
seroprevalence is high and case-fatality ratios are <30%
(9,13,15). This finding is in contrast to the findings of han-
taviruses with severe clinical syndromes and high death
rate (i.e., Sin Nombre and Andes viruses, both of which
have been associated with few subclinical infections). The
lack of subclinical infections can be caused by a variation
in virulence or by different genotypes of the hosts, which
give them greater resistance to infection and disease. 
A slightly disproportionate fraction of seropositive
samples (33%) were from Mapuche (18.3% of those sam-
pled were Mapuche). Moreover, when both hantavirus
seroprevalence and the HCPS incidence rates in this
region are considered, more infection but less disease (not
significant) is found in the Mapuche population (Table 3).
Future epidemiologic studies should address this finding
and use a larger sample to evaluate possible associations
between racial origin and the incidence rates of infection
and disease.
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